Skip to main content

Table 4 association with SEB-IgE in the patients with previously omalizumab treatment (n = 8)

From: Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis

 

SEB-IgE(+) n = 4

SEB-IgE(−) n = 4

p value

positive number with favours mepolizumab, n(%)

1 (25)

4 (100)

0.14a

ECRS as comorbidity, n(%)

2 (50)

4 (100)

0.43a

change from baseline in ACT score(pts)

4.5 (7.0)

3.8 (3.0)

0.77b

change from baseline in OCS dosec(%)

−4.8 (8.2)

−64 (41)

0.046b

change from baseline in exacerbation(%)

−8.8 (98)

−77 (42)

0.24b

  1. SEB-IgE Staphylococcus aureus enterotoxin B specific immunoglobulin E antibody, ECRS eosinophilic chronic rhinosinusitis, OMA omalizumab, ACT Asthma Control Test, OCS oral corticosteroid
  2. Data presented as mean (standard deviation), unless otherwise stated
  3. aFisher’s exact test
  4. bMann-Whitney U test
  5. cOCS doses are provided as prednisone equivalents
  6. There are three patients received maintenance OCS treatment in each groups